Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study

OBJECTIVE: Recycling tenofovir and lamivudine/emtricitabine (XTC) with dolutegravir would provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir with an optimized nucleoside reverse transcriptase inhibitor (NRTI) backbone. We evaluated efficacy of tenofovir/lamivudi...

Descripción completa

Detalles Bibliográficos
Autores principales: Keene, Claire M, Griesel, Rulan, Zhao, Ying, Gcwabe, Zimasa, Sayed, Kaneez, Hill, Andrew, Cassidy, Tali, Ngwenya, Olina, Jackson, Amanda, Van Zyl, Gert, Schutz, Charlotte, Goliath, Rene, Flowers, Tracy, Goemaere, Eric, Wiesner, Lubbe, Simmons, Bryony, Maartens, Gary, Meintjes, Graeme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612028/
https://www.ncbi.nlm.nih.gov/pubmed/33973876
http://dx.doi.org/10.1097/QAD.0000000000002936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612028/
https://www.ncbi.nlm.nih.gov/pubmed/33973876
http://dx.doi.org/10.1097/QAD.0000000000002936

Ejemplares similares